Exelon

   
Google
 
Web NewDrugInformation.com

Exelon


Drug - Exelon
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Rivastigmine Tartrate
Multiple ingredients are in alphabetical order.

Strength - EQ 1.5MG BASE
The potency of the active ingredient(s), Rivastigmine Tartrate. May repeat for multiple part products.

Applicant - NOVARTIS
The firm name holding legal responsibility for Exelon. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020823
The FDA assigned number to Exelon. Format is nnnnnn.

Product Number - 003
The FDA assigned number to identify Exelon. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Apr 21, 2000
The date Exelon was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Exelon. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Exelon is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novartis Pharmaceuticals Corp
The full name of the firm holding legal responsibility for the new application of Exelon.

Exelon